Insulin Resistance is Associated with Higher Cerebrospinal Fluid Tau Levels in Asymptomatic APOEɛ4 Carriers
Overview
Neurology
Authors
Affiliations
Background: Insulin resistance (IR) is linked with the occurrence of pathological features observed in Alzheimer's disease (AD), including neurofibrillary tangles and amyloid plaques. However, the extent to which IR is associated with AD pathology in the cognitively asymptomatic stages of preclinical AD remains unclear.
Objective: To determine the extent to which IR is linked with amyloid and tau pathology in late-middle-age.
Method: Cerebrospinal fluid (CSF) samples collected from 113 participants enrolled in the Wisconsin Registry for Alzheimer's Prevention study (mean age = 60.6 years), were assayed for AD-related markers of interest: Aβ₄₂, P-Tau181, and T-Tau. IR was determined using the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR). Linear regression was used to test the effect of IR, and APOEɛ4, on tau and amyloid pathology. We hypothesized that greater IR would be associated with higher CSF P-Tau181 and T-Tau, and lower CSF Aβ₄₂.
Results: No significant main effects of HOMA-IR on P-Tau181, T-Tau, or Aβ₄₂ were observed; however, significant interactions were observed between HOMA-IR and APOEɛ4 on CSF markers related to tau. Among APOEɛ4 carriers, higher HOMA-IR was associated with higher P-Tau181 and T-Tau. Among APOEɛ4 non-carriers, HOMA-IR was negatively associated with P-Tau181 and T-Tau. We found no effects of IR on Aβ₄₂ levels in CSF.
Conclusion: IR among asymptomatic APOEɛ4 carriers was associated with higher P-Tau181 and T-Tau in late-middle age. The results suggest that IR may contribute to tau-related neurodegeneration in preclinical AD. The findings may have implications for developing prevention strategies aimed at modifying IR in mid-life.
Role of Peripheral and Central Insulin Resistance in Neuropsychiatric Disorders.
Alagiakrishnan K, Halverson T J Clin Med. 2024; 13(21).
PMID: 39518747 PMC: 11547162. DOI: 10.3390/jcm13216607.
Shapiro A, Tjaden A, Edelstein S, Kahn S, Srikanthan P, Knowler W J Diabetes Complications. 2024; 38(6):108764.
PMID: 38701667 PMC: 11156481. DOI: 10.1016/j.jdiacomp.2024.108764.
Pharmacological Approaches Using Diabetic Drugs Repurposed for Alzheimer's Disease.
Adem M, Decourt B, Sabbagh M Biomedicines. 2024; 12(1).
PMID: 38255204 PMC: 10813018. DOI: 10.3390/biomedicines12010099.
Larsen B, Klinedinst B, Wolf T, McLimans K, Wang Q, Pollpeter A Physiol Behav. 2023; 271:114321.
PMID: 37567373 PMC: 10592072. DOI: 10.1016/j.physbeh.2023.114321.
The relationship of insulin resistance and diabetes to tau PET SUVR in middle-aged to older adults.
Ennis G, Betthauser T, Langhough Koscik R, Chin N, Christian B, Asthana S Alzheimers Res Ther. 2023; 15(1):55.
PMID: 36932429 PMC: 10022314. DOI: 10.1186/s13195-023-01180-2.